Figure 1.
Two groups were enrolled: biological treatment group (BT group) and traditional treatment group (TT group). The BT group was further subdivided under drug criteria: omalizumab group and mepolizumab group. All groups were tested at different times: T0 (first administration of the biologic agent); T1 (after 1 month); T3 (after 3 months); T6 (after 6 months).